Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia.

Journal of clinical lipidology - 1 Jan 2000

Defesche Joep C, Stefanutti Claudia, Langslet Gisle, Hopkins Paul N, Seiz Werner, Baccara-Dinet Marie T, Hamon Sara C, Banerjee Poulabi, Kastelein John J P

Abstract excerpt

BACKGROUND: Mutation(s) in genes involved in the low-density lipoprotein receptor (LDLR) pathway are typically the underlying cause of familial hypercholesterolemia. OBJECTIVE: The objective of the study was to examine the influence of genotype on treatment responses with alirocumab. METHODS: Patients from 6 trials (n = 1191, including 758 alirocumab-treated; Clinicaltrials.gov identifiers: NCT01266876;...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Apolipoprotein B-100

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Pharmacological

Share to Drug-Related Side Effects and Adverse Reactions

Share to Endosomal Sorting Complexes Required for Transport

Share to Hyperlipoproteinemia Type II

Share to Proprotein Convertase 9

Share to Receptors, LDL

Source

Identifiers

PMID: 28964736
DOI: 10.1016/j.jacl.2017.08.016

Genes

LDLR
APOB
PCSK9

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia.PMID 28964736Read ↗

Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia.Semantic proximity Read ↗

Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody.Semantic proximity Read ↗

Efficacy and Safety of Alirocumab in Patients With Autosomal Dominant Hypercholesterolemia Associated With Proprotein Convertase Subtilisin/Kexin Type 9 Gain-of-Function or Apolipoprotein B Loss-of-Function Mutations.Semantic proximity Read ↗

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives.Semantic proximity Read ↗

Next-generation sequencing to confirm clinical familial hypercholesterolemiaSemantic proximity Read ↗

Clinical characteristics and lipid management of patients with familial hypercholesterolemia: results from a 7 years single-centre experience.Semantic proximity Read ↗

Association between causative mutations and response to PCSK9 inhibitor therapy in subjects with familial hypercholesterolemia: A single center real-world study.Semantic proximity Read ↗

Widening the spectrum of genetic testing in familial hypercholesterolaemia: Will it translate into better patient and population outcomes?Semantic proximity Read ↗

Next-generation sequencing to confirm clinical familial hypercholesterolemia.Semantic proximity Read ↗

Exome Sequencing Enhances Screening for Familial Hypercholesterolemia Within a Multi-Site Healthcare SystemSemantic proximity Read ↗

The Spectrum of Low-Density Lipoprotein Receptor Mutations in a Large Turkish Cohort of Patients with Familial Hypercholesterolemia.Semantic proximity Read ↗

Management and Consequences of Genotype-Positive Familial Hypercholesterolemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.